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Introduction 
Trans-differentiation, the process of converting from one cell type to another without going 
through a pluripotent state, has great promise for regenerative medicine. However, the 
identification of key transcription factors to directly reprogram the identity of cell types is 
currently limited by the cost of exhaustive experimental testing of plausible sets of factors, an 
approach that is inefficient and unscalable. Here we present a predictive computational 
framework (Mogrify) that combines gene expression data with regulatory network information to 
predict the reprogramming factors necessary to induce cell conversion. We have applied 
Mogrify to 173 human cell types and 134 tissues, defining an atlas of cellular reprogramming. 
Mogrify correctly predicts transcription factors used in known trans-differentiations. 
Furthermore we validated two novel trans-differentiations predicted by Mogrify. We provide a 
practical and efficient mechanism for systematically implementing novel cell conversions, 
facilitating the generalization of the reprogramming of human cells. All predictions are made 
openly accessible to the community to help rapidly further the field of cell conversion 
(www.mogrify.net). 
 
We now know that it is possible to switch the phenotype of one somatic cell type to another. This 
epigenetic re-wiring process can be artificially managed and even reversed with the use of 
transcription factors (TFs)1. The best-known example is the reprogramming of somatic cells into 
induced pluripotent stem (iPS) cells by the introduction of four exogenous factors (Oct3/4, Sox2, 
c-Myc and Klf4)2,3. Previous and subsequent reports have demonstrated that other cell types can 
also be obtained by direct trans-differentiation using the same strategy4–9.  These discoveries 
came about through a process of exhaustive testing of large sets of TFs selected with expert 
knowledge. With roughly 2000 different TFs10–12 and approximately 400 unique cell types in 
humans13, the space of possible sets is very large (> 1011 combinations of 3 factors across 400 
cell types) and discovery will advance slowly using an educated trial and error approach. There 
are a number of existing algorithms that identify TFs that might assist in cell-to-cell conversions 
considering both epigenetic factors and transcription factor activation14–17. More recently 
approaches such as CellNet18,19 and a new entropy based method20 have provided larger scale 
predictions for transcription factors to convert into many cell types, as well as showing 
experimentally that these predictions are able to control cell identity. Herein, we present a 
comprehensive atlas of predictions for a large number of cell conversions, which we have 
implemented using a network-based computational framework (Mogrify) applied to the 
FANTOM5 datasets21 which includes ~300 different cell and tissue types. We have shown that 
we are able to independently recover (via prediction), the human conversion factors that were 
previously discovered experimentally and more importantly we have predicted and validated two 
new conversions. 
In order to predict the sets of TFs required for each cell conversion we identify those TFs that are 
not only differentially expressed between cell types, but also exert regulatory influence on other 
differentially expressed genes in the local network (see Figure 1a). A single score that captures 
the differential expression for every gene in every cell type is defined by combining the log-fold 
change and adjusted p-value.  The regulatory influence of each TF in each cell type is calculated 
by performing a weighted sum of the differential expression scores over the known interactome 
(as defined by STRING and MARA, see Figure 1c). This sum is weighted by two factors: (1) by 
the directness of the regulation, i.e. how many intermediates between the TF and a downstream 
gene, and (2) the specificity, i.e. the number of other genes the upstream TF also regulates. This 
weighted sum allows TFs to be ranked in each cell type according to their influence. The final 
step is to select the optimal set of TFs with the greatest combined influence over genes 
differentially expressed in the target cell type compared to the donor. This is done by adding TFs 
to the set in order of rank by differential influence, omitting those which don’t increase the 
influence of the set, until the combined influence reaches 98% of expressed target cell genes (see 
Figure 1d and online materials and methods). Biologically speaking, Mogrify identifies TFs 
which control the parts of the regulatory network most responsible for the identity of the target 
cell type.  
In order to assess the predictive power of Mogrify we first determined how Mogrify performs 
against well-known, previously published direct cell conversions, focusing on those involving 
human cells. These should not be considered as absolute perfect combinations, but as positive 
example reference points useful for comparison. As shown in Figure 2, in almost every case 
Mogrify predicts the complete set of TFs previously demonstrated to work, but sometimes 
includes an upstream TF in lieu of the published factor. For example, it is known that human 
fibroblasts can be converted to iPS cells by introducing OCT4 (also known as POU5F1), SOX2, 
KLF4 and MYC3 or OCT4, SOX2, NANOG and LIN2822. Mogrify predicts NANOG, OCT4 and 
SOX2 as the top 3 TFs for this conversion, a combination that has also been experimentally 
validated23. Seminal work by the Graf lab demonstrated that the conversion of B-cells and 
fibroblasts into macrophage-like cells was possible by the expression of CEBPa and PU.1 (also 
known as SPI1)24,25 which Mogrify perfectly predicts. For the conversion of human dermal 
fibroblasts into cardiomyocytes, we chose to not use the data in the FANTOM5 set since it lacks 
many key cardiomyocyte genes (indicating a deficiency in the origin of the sample). 
Nevertheless using the heart sample, which is a cellularly heterogeneous tissue and not ideal, 
Mogrify’s predicted list includes four out of the five TFs (or a closely related factor) used in the 
human conversion26. There are a number of reports in the literature of transdifferentiations from 
various cell types to neurons in both mouse and human (Table S1). The sets of TFs used vary, 
probably due to the heterogeneity and complexity of neurons, however factors common to all 
experiments27 are predicted by Mogrify (Table S2). Finally between human fibroblasts and 
hepatocytes, Mogrify predicts a combination of TFs highly similar to that required for 
conversion and maturation (Figure 2)6,28,29. Using the conversions shown in Figure 2 we assessed 
the ability of Mogrify, CellNet and the entropy-based approach from D’Alessio et al20 to recover 
these known factors. The average recovery rate of the published transcription factors for Mogrify 
was 84%, for CellNet 31% and D’Alessio et al 51% (see supplementary Figure S2 for details). In 
six out of the ten conversions in Figure 2 Mogrify recovered 100% of the required TFs, meaning 
that if Mogrify had been used to provide the TF set for these conversions, the experiment could 
have been a success first time. On the other hand CellNet and D’Allesio et al only recovered all 
factors for one of the ten conversions. It is important to note that the conversions proposed by 
CellNet and D’Allesio et al may also work, as the published conversions represent only one 
positive example of success. 
 
 
In order to empirically demonstrate the predictive capabilities of Mogrify we conducted two 
novel cell conversions using human cells. 1) Human Fibroblast to Keratinocyte (iKer) 
conversion: For this conversion, cells were transduced with FOXQ1, SOX9, MAFB, CDH1, FOS 
and REL, predicted by Mogrify (Figure 3A and supplementary Table S3). By day 16 post-
transduction, keratinocyte-associated markers keratin1, keratin14 and involucrin, were markedly 
up-regulated in the transdifferentiated cells (Figure 3C). Moreover, within three weeks, the 
majority of transduced cells exhibited cobblestone morphology, a classic characteristic displayed 
by keratinocytes. Adjacent un-transduced GFP negative cells or control cells transduced with 
GFP-only viruses maintained their fibroblastic morphology (arrow in Figure 3D). This 
morphological and molecular characterization of the reprogrammed cells indicates that Mogrify 
successfully predicts the TFs necessary to induce the conversion from human fibroblasts to 
keratinocyte-like cells. 2) Adult Human Keratinocyte (HEKa) to Microvascular Endothelial 
cells (iECs): For this conversion we selected SOX17, TAL1, SMAD1, IRF1 and TCF7L1 to be 
used from the seven TFs suggested by Mogrify (Figure 3E and supplementary Table S4). These 
five TFs are predicted to regulate ~92% of the required genes for iECs. Once these TFs were 
over-expressed in the HEKa cells we determined that the cells needed to be kept in their media 
until day four (Figure 3F). We used FACS to follow the kinetics of the cell reprogramming, 
using the well-established endothelial marker CD31 (Figure 3G), and by day 14 after 
transduction we detected that more than 2% of the infected cells had up-regulated CD31 and by 
day 18 almost 10% had up-regulated CD31. At that point we isolated those CD31 cells and 
evaluated the expression of the endothelial-associated genes (CD31, VE-Cadherin, and 
VEGFR2) by qPCR which resulted in a clear reactivation of all the assessed genes (Figure 3H). 
Finally, we performed immunofluorescence (IF) to verify the morphology and expression of the 
trans-differentiated cells. As shown in Figure 3I, only the cells transduced with the predicted TFs 
-and not the control cells- presented the right morphology and expressed CD31 and VE-Cadherin 
on the surface. This morphology and molecular characterization of the reprogrammed cells 
indicates the successful transition of human keratinocytes into human endothelial-like cells. 
There have been several reports supporting the idea that the Yamanaka factors can be used to 
initiate transdifferentiation without traversing the pluripotent state (reviewed in Firas Et  al 
20151). This has been recently challenged by the groups of Hochedlinger and Hanna30,31. We 
observe that Mogrify did not predict the use of Yamanaka factors for the transdifferentiations 
mentioned in this paper (except to iPS cells). Mogrify prediction however is based on the source 
and target regulatory networks and does not have the capacity to detect factors only transiently 
expressed during the reprogramming process. 
Since Conrad Waddington depicted the first epigenetic landscape, several attempts have been 
made to produce a more representative cellular landscape32–34 but have focused on one or two 
cell types and are based on path-integral quasi-potentials, mechanistic modeling or probability 
landscapes. We hypothesised that comparing all-against-all TF network differences as 
determined by Mogrify in combination with the transcriptional profiles would allow the creation 
of a 3D landscape representing human cell type (Figures S3 and S4). The landscape places those 
cell types that are molecularly similar close together in the x-y plane, and adjusts the height (z 
direction) according to how likely a cell type is to be a good starting cell source (see online 
materials and methods for details). Interestingly, we observe that different stem cells are placed 
in the highest locations. This may suggest that the transcriptional networks of those cells at the 
highest points in the landscape are controlled by fewer TFs, and that the more differentiated the 
cell becomes (in the valleys) the more TFs are needed to fine tune the transcriptional network.  
 
Having mapped the landscape of human cell type in terms of naturally-occurring states and the 
transitions between them, we note that a core control set of TFs that describe the individual cell 
types is captured, even though the primary aim of Mogrify is to predict TFs for cellular 
conversions. We believe that this per se could aid researchers to unveil the role of different TFs 
in their favourite cell type. In practice Mogrify provides a significant advance over the strategies 
currently being applied in laboratories for cell reprogramming, helping in the prediction of TFs 
whose over-expression will induce directed cell conversion. Mogrify has been pre-calculated on 
conversions between all possible combinations of the 307 FANTOM5 tissue/cell types resulting 
in 93,942 directed conversions and provided online (www.mogrify.net) via an interface for 
guiding experimentation and exploring the cellular landscape. Whilst it is likely that some trial 
and error will still be involved for some conversions, Mogrify provides a starting point and 
systematic means to explore new conversions in human. Because Mogrify incorporates a TF 
redundancy step, it is able to give a finite set of TFs as a prediction for the cell conversion, which 
is of more utility than just the ranking of all TFs. Although Mogrify has taken advantage of the 
rich FANTOM5 data, MARA and STRING, these databases have their own limitations which 
will impart some restrictions on Mogrify’s predictions. For example, the FANTOM5 is in some 
instances limited to few replicates and there is a possible heterogeneity of some samples. MARA 
relies on known DNA binding motifs to estimate binding to target genes, knowledge that is 
incomplete. STRING is incomplete in other ways but future rises in the abundance of empirical 
data on TF interactions and binding in diverse cell types will help to improve Mogrify. It should 
be noted that Mogrify as well as other methods finds positive regulators of the target cell and 
does not interrogate the extinction of the source cell signature. This may result in less faithful 
conversions, mitigated by the downregulation of source genes that has been observed after 
introduction of core target TFs (e.g. in Polo el al, 201235). Mogrify predictions will not always 
guarantee conversion, but will certainly aid transdifferentiation protocols. Other players like non-
coding RNAs, small molecules, epigenetic factors and signaling pathways provide a rich source 
of improvements for the future. At present the major challenge to progress in the field of 
reprogramming is in increasing the number of successful cell conversions. That is what this 
resource makes possible, paving the way for the routine manipulation of cells, an understanding 
of the processes involved, and the immediate translation of any breakthroughs in the clinical 
delivery techniques under heavy development in academia and in industry. 
 
Acknowledgements 
 
JG and OR were supported by grants from the Biotechnology and Biological Sciences research council 
and the Japan Society for the Promotion of Science. JMP was supported by a Silvia and Charles Senior 
Medical Viertel Fellowship, the Metcalf award from the National Stem Cell Foundation of Australia, an 
NHMRC project grant APP1085302 and the Australia Research Council’s special initiative Stem Cells 
Australia. FANTOM5 was made possible by a Research Grant for RIKEN Omics Science Center from 
MEXT to Yoshihide Hayashizaki and a grant of the Innovative Cell Biology by Innovative Technology 
(Cell Innovation Program) from the MEXT, Japan to Y.H.. We would like to thank all members of the 
FANTOM5 consortium for contributing to generation of samples and analysis of the dataset and thank 
GeNAS for data production.  
 
Author Contributions: 
 
O.J.L.R. and J.G. initiated the project on the basis of discussions with Y.H. about FANTOM5. J.M.P. led 
the experimental contribution and helped further develop the Mogrify algorithm. J.F. performed all the 
experimental validations with the contribution of M.H., A.K and C.N. O.J.L.R. performed the data 
analysis and interpretation, with significant input by J.G. in the early stages of the work. O.L.J.R., J.M.P. 
and J.G. prepared the manuscript with input from all named authors at various stages. M.E.O and H.F. 
provided help and advice with technical aspects of the implementation. H.S. and J.W.S. were involved in 
early discussion of cell conversion concepts. A.R.R.F. and C.O.D were involved in the FANTOM5 
management. 
 
Online Methods 
 
 
 
References: 
 
1. Firas, J., Liu, X., Lim, S. M. & Polo, J. M. Transcription factor-mediated reprogramming: 
epigenetics and therapeutic potential. Immunol. Cell Biol. 93, 284–289 (2015). 
 
2. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic 
and adult fibroblast cultures by defined factors. Cell 126, 663–76 (2006). 
 
3. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by 
defined factors. Cell 131, 861–72 (2007). 
 
4. Vierbuchen, T. et al. Direct conversion of fibroblasts to functional neurons by defined 
factors. Nature 463, 1035–41 (2010). 
 
5. Ieda, M. et al. Direct Reprogramming of Fibroblasts into Functional Cardiomyocytes by 
Defined Factors. Cell 142, 375–386 (2010). 
 
6. Du, Y. et al. Human hepatocytes with drug metabolic function induced from fibroblasts by 
lineage reprogramming. Cell Stem Cell 14, 394–403 (2014). 
 
7. Sekiya, S. & Suzuki, A. Direct conversion of mouse fibroblasts to hepatocyte-like cells by 
defined factors. Nature 475, 390–3 (2011). 
 
8. Pfisterer, U. et al. Direct conversion of human fibroblasts to dopaminergic neurons. Proc. 
Natl. Acad. Sci. U. S. A. 108, 10343–8 (2011). 
 
9. Addis, R. C. et al. Optimization of direct fibroblast reprogramming to cardiomyocytes 
using calcium activity as a functional measure of success. J. Mol. Cell. Cardiol. 60, 97–
106 (2013). 
 
10. Wilson, D., Charoensawan, V., Kummerfeld, S. K. & Teichmann, S. A. DBD--
taxonomically broad transcription factor predictions: new content and functionality. 
Nucleic Acids Res. 36, D88–92 (2008). 
 
11. Vaquerizas, J. M., Kummerfeld, S. K., Teichmann, S. a & Luscombe, N. M. A census of 
human transcription factors: function, expression and evolution. Nat. Rev. Genet. 10, 252–
63 (2009). 
 
12. Fulton, D. L. et al. TFCat: the curated catalog of mouse and human transcription factors. 
Genome Biol. 10, R29 (2009). 
 
13. Vickaryous, M. K. & Hall, B. K. Human cell type diversity, evolution, development, and 
classification with special reference to cells derived from the neural crest. Biol. Rev. 
Camb. Philos. Soc. 81, 425–55 (2006). 
 
14. Heinäniemi, M. et al. Gene-pair expression signatures reveal lineage control. Nat. 
Methods 10, 577–83 (2013). 
 
15. Lang, A. H., Li, H., Collins, J. J. & Mehta, P. Epigenetic landscapes explain partially 
reprogrammed cells and identify key reprogramming genes. PLoS Comput. Biol. 10, 
e1003734 (2014). 
 
16. Del Sol, I. C. A. A general strategy for cellular reprogramming: The importance of 
transcription factor cross-repression. Stem Cells 31, 2127–2135 (2013). 
 
17. Davis, F. P. & Eddy, S. R. Transcription Factors That Convert Adult Cell Identity Are 
Differentially Polycomb Repressed. PLoS One 8, 1–8 (2013). 
 
18. Morris, S. A. et al. Dissecting Engineered Cell Types and Enhancing Cell Fate 
Conversion via CellNet. Cell 158, 889–902 (2014). 
 
19. Cahan, P. et al. CellNet: Network Biology Applied to Stem Cell Engineering. Cell 158, 
903–915 (2014). 
 
20. D’Alessio, A. C. et al. A Systematic Approach to Identify Candidate Transcription Factors 
that Control Cell Identity. Stem Cell Reports (2015). doi:10.1016/j.stemcr.2015.09.016 
 
21. Forrest, A. R. R. et al. A promoter-level mammalian expression atlas. Nature 507, 462–
470 (2014). 
 22. Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 
318, 1917–20 (2007). 
 
23. Huangfu, D. et al. Induction of pluripotent stem cells from primary human fibroblasts with 
only Oct4 and Sox2. Nat. Biotechnol. 26, 1269–1275 (2008). 
 
24. Xie, H., Ye, M., Feng, R. & Graf, T. Stepwise Reprogramming of B Cells into 
Macrophages. Cell 117, 663–676 (2004). 
 
25. Rapino, F. et al. C/EBPα induces highly efficient macrophage transdifferentiation of B 
lymphoma and leukemia cell lines and impairs their tumorigenicity. Cell Rep. 3, 1153–63 
(2013). 
 
26. Fu, J.-D. et al. Direct reprogramming of human fibroblasts toward a cardiomyocyte-like 
state. Stem cell reports 1, 235–47 (2013). 
 
27. Zou, Q. et al. Direct conversion of human fibroblasts into neuronal restricted progenitors. 
J. Biol. Chem. 289, 5250–60 (2014). 
 
28. Huang, P. et al. Induction of functional hepatocyte-like cells from mouse fibroblasts by 
defined factors. Nature advance on, (2011). 
 
29. Kogiso, T., Nagahara, H., Otsuka, M., Shiratori, K. & Dowdy, S. F. Transdifferentiation 
of human fibroblasts into hepatocyte-like cells by defined transcriptional factors. Hepatol. 
Int. 7, 937–944 (2013). 
 
30. Bar-Nur, O. et al. Lineage conversion induced by pluripotency factors involves transient 
passage through an iPSC stage. Nat. Biotechnol. 33, 1–11 (2015). 
 
31. Maza, I. et al. Transient acquisition of pluripotency during somatic cell 
transdifferentiation with iPSC reprogramming factors. Nat. Biotechnol. 33, 769–774 
(2015). 
 
32. Qiu, X., Ding, S. & Shi, T. From understanding the development landscape of the 
canonical fate-switch pair to constructing a dynamic landscape for two-step neural 
differentiation. PLoS One 7, e49271 (2012). 
 
33. Bhattacharya, S., Zhang, Q. & Andersen, M. E. A deterministic map of Waddington’s 
epigenetic landscape for cell fate specification. BMC Syst. Biol. 5, 85 (2011). 
 
34. Flöttmann, M., Scharp, T. & Klipp, E. A stochastic model of epigenetic dynamics in 
somatic cell reprogramming. Front. Physiol. 3, 216 (2012). 
 
35. Polo, J. M. et al. A molecular roadmap of reprogramming somatic cells into iPS cells. Cell 
151, 1617–1632 (2012). 
 
36. Anders, S. & Huber, W. Differential expression analysis for sequence count data. (2010). 
doi:10.1038/npre.2010.4282.2 
 
37. Lattanzi, L. et al. High efficiency myogenic conversion of human fibroblasts by 
adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene 
therapy of primary myopathies. J. Clin. Invest. 101, 2119–28 (1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figures 
 
 
 
Figure 1. The Mogrify algorithm for predicting TFs for cell conversion. This is done as 
follows: (A) Mogrify aims to find those TFs that not only are differentially expressed but appear 
to be responsible for the regulation of many differentially expressed genes in a given cell type. 
(B) We use the cell type ontology tree created as part of the FANTOM5 consortium 21 to select 
an appropriate background for DESeq 36 to calculate the adjusted p-value and log fold change for 
genes in the sample. (C) For each TF we construct a local network neighborhood of influence 
weighting the downstream effect on a gene by its connected distance and the out-degree of its 
parent. (D) We maximise regulatory coverage by removing TFs which are redundant in their 
influence over other factors. 
 
 
 
 
 
Figure 2. Mogrify predictions for some of the known trans-differentiations that are 
published in the literature. TFs that Mogrify correctly identifies from the published list are 
highlighted. Samples are grouped using the FANTOM cell ontology 21. For each publication the 
transcription factors that are in the initial maximum coverage set are shown in green and in the 
overall predicted Mogrify set in orange. For instance the transdifferentiation between fibroblast 
and myoblast 37 required only MYOD and this was identified by Mogrify. 
 
 
Figure 3. Empirical validation of novel conversions predicted by Mogrify 
(A) The transcription factor network predicted by Mogrify to be involved in the dermal fibroblast 
to keratinocyte transdifferentiation. (B) An outline of the method used for the transdifferentiation 
assay. (C) qPCR analysis of the indicated markers in cells harvested at days 12-16 during 
transdifferentiation. All values are experimental replicates and are relative to gene expression in 
dermal fibroblasts (n=3). (D) Brightfield and GFP images at day 24 showing the cobblestone 
morphology of transdifferentiated cells (upper panel) and GFP+ control cells (lower panel). (E) 
A schematic representation of the transcription factor network predicted by Mogrify to be 
involved in the keratinocyte to microvascular endothelial cell transdifferentiation. (F) An outline 
of the method used for the transdifferentiation assay. (G) Flow cytometric analysis of CD31 
expression at day 0, 14 and 18 of transdifferentiation. (H) qPCR analysis of the indicated 
expression markers in CD31+ cells harvested at day 18 of transdifferentiation. All values are 
experimental replicates and are relative to gene expression in keratinocytes (n=3). (I) 
Immunofluorescence analysis of endothelial markers CD31 and VE-Cadherin at day 18 for 
vector free control cells (a) and transdifferentiating cells (b-f). Scale bar = 50μm.  
